Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Brandi Robinson - Senior Vice President of Corporate Affairs Douglas Williamson - Chief Medical Officer Gregory Divis - Chief Executive Officer Jennifer Gudeman - Vice President of Medical & Clinical Affairs Richard Kim - Chief Commercial Officer Tom McHugh - Senior Vice President & Chief Financial Officer Conference Call Participants Francois Brisebois - Oppenheimer Marc Goodman - SVB Secur ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q4 2021 Earnings Conference Call March 17, 2022 8:30 AM ET Company Participants Brandi Robinson - Senior Vice President, Corporate Affairs Gregory Divis - Chief Executive Officer Douglas Williamson - Chief Medical Officer Tom McHugh - Chief Financial Officer Richard Kim - Chief Commercial Officer Conference Call Participants Christopher Howerton - Jefferies David Amsellem - Piper Sandler & Co. Ami Fadia - Needham & Co. Paul Matteis - Stifel Oren Livnat - H.C. Wainwri ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q3 2021 Earnings Conference Call November 8, 2021 8:30 AM ET Company Participants Courtney Turiano - Investor Relations Gregory Divis - Chief Executive Officer Tom McHugh - Chief Financial Officer Richard Kim - Chief Commercial Officer Jennifer Gudeman - Vice President of Medical and Clinical Affairs Conference Call Participants Christopher Howerton - Jefferies Francois Brisebois - Oppenheimer & Co. Inc. Ami Fadia - Needham & Co. Rudy Li - SVB Leerink David Amsellem ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q2 2021 Earnings Conference Call August 9, 2021 8:30 AM ET Company Participants Courtney Turiano - Investor Relations Gregory Divis - Chief Executive Officer Tom McHugh - Chief Financial Officer Richard Kim - Chief Commercial Officer Jennifer Gudeman - Vice President of Medical and Clinical Affairs Conference Call Participants Paul Matteis - Stifel David Amsellem - Piper Sandler Francois Brisebois - Oppenheimer Oren Livnat - HC Wainwright Robin Garner - Craig -Hallum ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-28508 ——————— AVADEL PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) ——————— (State or Other Ju ...